Switching P2Y12 Receptor Inhibiting Therapies

Interventional Cardiology Clinics

Volumn 6, Issue 1, 2017, Pages 67-89

  Rollini, Fabiana ^a   Franchi, Francesco ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cangrelor; Clopidogrel; P2Y12 receptor inhibitors; Prasugrel; Switching; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DUAL ANTIPLATELET THERAPY; HUMAN; PHARMACODYNAMIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; THROMBOSIS;

ACUTE CORONARY SYNDROME; DRUG SUBSTITUTION; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THROMBOSIS;

EID: 84997079037     PISSN: 22117458     EISSN: 22117466     Source Type: Journal    
DOI: 10.1016/j.iccl.2016.08.006     Document Type: Review

References (71)

1. 1 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124 (2011), e574–e651.
2. 2 O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 (2013), 529–555.
3. 3 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130 (2014), e344–e426.
4. 4 Authors/Task Force Members, Windecker, S., Kolh, P., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
5. 5 Sherwood, M.W., Wiviott, S.D., Peng, S.A., et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc, 3, 2014, e000849.
6. 6 Bueno, H., Sinnaeve, P., Annemans, L., et al. Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. Eur Heart J Acute Cardiovasc Care 5 (2016), 3–12.
7. 7 Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
8. 8 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
9. 9 Franchi, F., Angiolillo, D.J., Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12 (2015), 30–47.
10. 10 Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
11. 11 Franchi, F., Rollini, F., Muñiz-Lozano, A., et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 11 (2013), 1279–1291.
12. 12 Cangrelor United States full prescribing information. Available at: http://www.kengreal.com/pdfs/kengreal-us-prescribing-information.pdf. Accessed July 30, 2016.
13. 13 Angiolillo, D.J., Ueno, M., Goto, S., Basic principles of platelet biology and clinical implications. Circ J 74 (2010), 597–607.
14. 14 Angiolillo, D.J., The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 72 (2012), 2087–2116.
15. 15 Farid, N.A., Kurihara, A., Wrighton, S.A., Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50 (2010), 126–142.
16. 16 Price, M.J., Walder, J.S., Baker, B.A., et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol 59 (2012), 2338–2343.
17. 17 Husted, S., van Giezen, J.J., Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 27 (2009), 259–274.
18. 18 Gurbel, P.A., Bliden, K.P., Butler, K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120 (2009), 2577–2585.
19. 19 Roe, M.T., Armstrong, P.W., Fox, K.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
20. 20 Payne, C.D., Li, Y.G., Brandt, J.T., et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 19 (2008), 275–281.
21. 21 Wiviott, S.D., Trenk, D., Frelinger, A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007), 2923–2932.
22. 22 Montalescot, G., Sideris, G., Cohen, R., et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103 (2010), 213–223.
23. 23 Angiolillo, D.J., Saucedo, J.F., Deraad, R., et al., SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56 (2010), 1017–1023.
24. 24 Trenk, D., Stone, G.W., Gawaz, M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59 (2012), 2159–2164.
25. 25 Diodati, J.G., Saucedo, J.F., French, J.K., et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv 6 (2013), 567–574.
26. 26 Rollini, F., Franchi, F., Cho, J.R., et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J, 2016 [pii:ehv744].
27. 27 Sardella, G., Calcagno, S., Mancone, M., et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv 5 (2012), 698–704.
28. 28 Lhermusier, T., Voisin, S., Murat, G., et al. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol 174 (2014), 874–876.
29. 29 Alexopoulos, D., Galati, A., Xanthopoulou, I., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60 (2012), 193–199.
30. 30 Koul, S., Andell, P., Martinsson, A., et al. A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC Cardiovasc Disord, 14, 2014, 189.
31. 31 Cuisset, T., Gaborit, B., Dubois, N., et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol 168 (2013), 523–528.
32. 32 Nührenberg, T.G., Trenk, D., Leggewie, S., et al. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets 24 (2013), 549–553.
33. 33 Parodi, G., De Luca, G., Bellandi, B., et al. Switching from clopidogrel to prasugrel in patients having coronary stent implantation. J Thromb Thrombolysis 38 (2014), 395–401.
34. 34 Aradi, D., Tornyos, A., Pintér, T., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63 (2014), 1061–1070.
35. 35 Mayer, K., Schulz, S., Bernlochner, I., et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost 112 (2014), 342–351.
36. 36 Lhermusier, T., Lipinski, M.J., Drenning, D., et al. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol 27 (2014), 365–372.
37. 37 Gurbel, P., Bliden, K.P., Butler, K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (2010), 1188–1199.
38. 38 Caiazzo, G., De Rosa, S., Torella, D., et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ Cardiovasc Interv 7 (2014), 104–112.
39. 39 Hibbert, B., Maze, R., Pourdjabbar, A., et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One, 9, 2014, e92078.
40. 40 Michelson, A.D., Frelinger, A.L. 3rd, Braunwald, E., et al., TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30 (2009), 1753–1763.
41. 41 Saucedo, J.F., Angiolillo, D.J., DeRaad, R., et al. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 109 (2013), 347–355.
42. 42 Bliden, K.P., Tantry, U.S., Storey, R.F., et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 162 (2011), 160–165.
43. 43 Storey, R.F., Angiolillo, D.J., Patil, S.B., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56 (2010), 1456–1462.
44. 44 Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
45. 45 Bagai, A., Peterson, E.D., Honeycutt, E., et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care 4 (2015), 499–508.
46. 46 Alexopoulos, D., Xanthopoulou, I., Deftereos, S., et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 167 (2014), 68–76.e2.
47. 47 De Luca, L., Leonardi, S., Cavallini, C., et al. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. Eur Heart J Acute Cardiovasc Care 4 (2015), 441–452.
48. 48 Clemmensen, P., Grieco, N., Ince, H., et al. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel - the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care 4 (2015), 220–229.
49. 49 Schiele, F., Puymirat, E., Bonello, L., et al. Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart, 3, 2016, e000384.
50. 50 Bagai, A., Wang, Y., Wang, T.Y., et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 7 (2014), 585–593.
51. 51 De Luca, G., Verdoia, M., Schaffer, A., et al. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. J Thromb Thrombolysis 38 (2014), 388–394.
52. 52 Loh, J.P., Pendyala, L.K., Kitabata, H., et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 111 (2013), 841–845.
53. 53 Almendro-Delia, M., Blanco Ponce, E., Gomez-Domínguez, R., et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. J Thromb Thrombolysis 39 (2015), 499–507.
54. 54 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
55. 55 Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
56. 56 Bonaca, M.P., Bhatt, D.L., Ophuis, T.O., et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol 1 (2016), 425–432.
57. 57 Pourdjabbar, A., Hibbert, B., Simard, T., et al. Optimizing crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome: the CAPITAL OPTI-CROSS randomized trial. J Am Coll Cardiol, 65(10 Suppl), 2015.
58. 58 Kerneis, M., Silvain, J., Abtan, J., et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv 6 (2013), 158–165.
59. 59 Deharo, P., Pons, C., Pankert, M., et al. Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Int J Cardiol 168 (2013), 5004–5005.
60. 60 Angiolillo, D.J., Curzen, N., Gurbel, P., et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (switching anti platelet-2). J Am Coll Cardiol 63 (2014), 1500–1509.
61. 61 Franchi, F., Faz, G.T., Rollini, F., et al. Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study. JACC Cardiovasc Interv 9 (2016), 1089–1098.
62. 62 Steinhubl, S.R., Oh, J.J., Oestreich, J.H., et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121 (2008), 527–534.
63. 63 Dovlatova, N.L., Jakubowski, J.A., Sugidachi, A., et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6 (2008), 1153–1159.
64. 64 Rollini, F., Franchi, F., Tello-Montoliu, A., et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc Interv 7 (2014), 426–434.
65. 65 Schneider, D.J., Agarwal, Z., Seecheran, N., et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv 7 (2014), 435–442.
66. 66 Schneider, D.J., Seecheran, N., Raza, S.S., et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis 26 (2015), 42–48.
67. 67 Schneider, D.J., Agarwal, Z., Seecheran, N., et al. Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation. J Interv Cardiol 28 (2015), 415–419.
68. 68 Franchi, F., Rollini, F., Park, Y., et al. A safety evaluation of cangrelor in patients undergoing PCI. Expert Opin Drug Saf 15 (2016), 275–285.
69. 69 Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
70. 70 Angiolillo, D.J., Schneider, D.J., Bhatt, D.L., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 34 (2012), 44–55.
71. 71 Mehran, R., Baber, U., Steg, P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382 (2013), 1714–1722.